Avalo Therapeutics, Inc. (AVTX) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead asset, AVTX-009, is currently in a Phase 2 clinical trial (LOTUS) for hidradenitis suppurativa (HS). The company reported completing enrollment in this trial in October 2025, with topline results expected in mid-2026.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0.25 million | $0 | $0.25 million |
| Net Loss | $(30.6) million | $23.0 million (Income) | $(64.5) million | $0.21 million (Income) |
| Operating Expenses | $19.2 million | $13.1 million | $53.2 million | $55.5 million |
| R&D Expenses | $13.6 million | $9.5 million | $36.8 million | $16.3 million |
| Cash & Equivalents | $27.0 million | $81.9 million | $27.0 million | $81.9 million |
| Short-term Investments | $84.7 million | $0 | $84.7 million | $0 |
| Total Liquidity | $111.6 million | $81.9 million | $111.6 million | $81.9 million |
| Derivative Liability | $23.2 million | $11.8 million | $23.2 million | $11.8 million |
Note: Revenue is zero as the Millipred license expired in September 2023. The company has no product sales currently.
Material Changes vs. Prior Period
- Net Loss vs. Income: The company reported a net loss of $30.6 million for Q3 2025, compared to net income of $23.0 million in Q3 2024. The prior year income was driven by a $36.0 million gain from the change in fair value of warrant liabilities, which were fully exercised in Q4 2024 and no longer impact current results.
- Derivative Liability Increase: The derivative liability increased to $23.2 million from $11.8 million in the prior year period. This resulted in a $12.5 million expense in Q3 2025 due to changes in fair value assumptions regarding the AVTX-007 milestones and royalties (specifically driven by Apollo's Phase 2a success in atopic dermatitis).
- Operating Expenses: R&D expenses increased by $4.1 million quarter-over-quarter, primarily due to clinical expenses for the Phase 2 LOTUS trial ($7.3 million vs. $5.1 million) and increased headcount.
- Liquidity Position: Total cash and short-term investments increased to $111.6 million from $81.9 million at the end of Q3 2024, despite a net cash burn of $37.2 million from operations YTD. This increase is due to the purchase of $84.7 million in short-term investments.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash and investments ($111.6 million) to fund operations for at least 12 months from the filing date and potentially into 2028. Future funding needs may be met through the At-The-Market (ATM) program, equity financings, or strategic collaborations.
- Key Milestone: The primary focus is the Phase 2 LOTUS trial for AVTX-009 in HS. Enrollment is complete, and topline data is expected in mid-2026. Future expenses beyond mid-2026 are highly dependent on these results.
- Risks:
- Derivative Liability Volatility: The fair value of the derivative liability is sensitive to unobservable inputs (probability of success, sales forecasts) for out-licensed assets (AVTX-007). Changes in these assumptions caused significant non-cash expenses in the current period.
- Liquidity: As a clinical-stage company with no revenue, Avalo relies on capital markets. Future equity raises will result in dilution.
- Development Risk: There is no guarantee that AVTX-009 will achieve regulatory approval or that the Phase 2 trial will meet its primary endpoints.
Investor Verification Checklist
- Cash Runway: Verify the $111.6 million liquidity figure against the projected burn rate to confirm the "into 2028" funding assertion.
- Derivative Liability Drivers: Review Note 6 to understand the specific assumptions (probability of success, peak sales) used to value the $23.2 million derivative liability, as these are Level 3 inputs and highly subjective.
- ATM Program Utilization: Monitor the $75.0 million ATM program capacity; $14.4 million was raised YTD 2025. Assess remaining capacity for future funding needs.
- Phase 2 LOTUS Trial Status: Confirm the timeline for the mid-2026 data readout and any potential delays in patient recruitment or data analysis.
- Stock-Based Compensation: Note the significant increase in SBC ($9.1 million YTD 2025 vs. $2.9 million YTD 2024) and its impact on future dilution and expense recognition.